Marshall Wace LLP Takes Position in Sanara MedTech Inc. (NASDAQ:SMTI)

Marshall Wace LLP acquired a new position in Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 30,285 shares of the company's stock, valued at approximately $1,005,000. Marshall Wace LLP owned about 0.35% of Sanara MedTech as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Fifth Third Bancorp bought a new position in shares of Sanara MedTech in the fourth quarter valued at approximately $898,000. Renaissance Technologies LLC boosted its holdings in Sanara MedTech by 152.9% in the 4th quarter. Renaissance Technologies LLC now owns 35,400 shares of the company's stock valued at $1,175,000 after purchasing an additional 21,400 shares during the period. JPMorgan Chase & Co. grew its position in shares of Sanara MedTech by 234.5% during the 4th quarter. JPMorgan Chase & Co. now owns 13,574 shares of the company's stock valued at $451,000 after purchasing an additional 9,516 shares in the last quarter. State Street Corp increased its holdings in shares of Sanara MedTech by 9.2% in the third quarter. State Street Corp now owns 58,688 shares of the company's stock worth $1,775,000 after purchasing an additional 4,932 shares during the period. Finally, Barclays PLC increased its holdings in shares of Sanara MedTech by 323.0% in the third quarter. Barclays PLC now owns 5,731 shares of the company's stock worth $174,000 after purchasing an additional 4,376 shares during the period. 8.10% of the stock is currently owned by institutional investors.

Sanara MedTech Stock Down 0.6 %

Shares of NASDAQ:SMTI opened at $31.94 on Thursday. The firm has a market capitalization of $283.88 million, a PE ratio of -32.26 and a beta of 1.47. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.02 and a current ratio of 2.23. Sanara MedTech Inc. has a 52-week low of $25.86 and a 52-week high of $39.08. The firm has a fifty day moving average of $31.30 and a 200 day moving average of $33.44.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01. The firm had revenue of $26.31 million during the quarter, compared to analysts' expectations of $22.75 million. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%. As a group, research analysts anticipate that Sanara MedTech Inc. will post -1.1 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Cantor Fitzgerald restated an "overweight" rating and issued a $46.00 target price on shares of Sanara MedTech in a research note on Wednesday, March 26th. HC Wainwright upped their price objective on shares of Sanara MedTech from $50.00 to $51.00 and gave the stock a "buy" rating in a research report on Wednesday, March 26th.

Sanara MedTech Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.

Want to see what other hedge funds are holding SMTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanara MedTech Inc. (NASDAQ:SMTI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.